deltatrials
Completed PHASE3 NCT00012324

Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer

A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin

Sponsor: Eximias Pharmaceutical

Conditions Liver Cancer
Interventions doxorubicin hydrochloride nolatrexed dihydrochloride
Updated 6 times since 2017 Last updated: Jun 25, 2013 Started: Sep 30, 2000 Completion: Nov 30, 2005

This PHASE3 trial investigates Liver Cancer and is currently completed. Eximias Pharmaceutical leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Sep 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eximias Pharmaceutical
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Baltimore, United States, Beverly Hills, United States, Chicago, United States, Cleveland, United States, Dallas, United States, Greenville, United States, Hackensack, United States, Honolulu, United States, Hudson, United States and 28 more location s